The NPPA’s memorandum mandates timely Form III submissions from all manufacturers under the DPCO, emphasizing increased scrutiny and potential enforcement for discrepancies. Companies must ensure compliance by identifying all qualifying entities, reconciling data, and maintaining robust records to avoid regulatory issues.
Please click here to read the full article by Sidharrth Shankar, Partner, and Eshika Phadke, Senior Associate, published in The Economic Times Pharma.
Sidharrth (Sid) is a seasoned corporate lawyer and also the co-chair of the corporate practice with a core focus on private equity and mergers & acquisitions. Sid has substantial experience advising global private equity funds, multinational corporations and strategic investors on complex cross-border transactions across a broad spectrum of industries over the last two and a half decades, with over two decades in JSA itself.